

Bureau of Infectious Disease Control

New Hampshire COVID-19 Vaccination Allocation Plan Summary January 16, 2021

Phase 1	Phase 2	Phase 3
Phase 1a (~110,000) High-risk health workers First responders Residents and staff of long-term care and assisted living facilities Phase 1b (~325,000) People ≥65 years old Medically vulnerable at significantly higher risk 2 or more conditions (see list) Family caregivers of those medically vulnerable persons, <16 years old, not eligible for vaccine Residents and staff of residential facilities for persons with intellectual and developmental disabilities Corrections officers and staff working in correctional facilities First responders and health workers not already vaccinated	Phase 2a (~75,000) • K-12 school and childcare staff Phase 2b (~200,000) • People 50 – 64 years old	Phase 3a (~325,000) • Medically vulnerable <50 years old at moderately higher risk with 1 or more conditions (see list) Phase 3b (~325,000) • Everyone else not already vaccinated
DECEMBER - MARCH *** Estimated timeframe depends on vaccine doses	MARCH - MAY	MAY AND BEYOND
*** Estimated timeframe depends on vaccine doses	allocated to New Hampshire from the feder	ral government and vaccine uptake***
Equity is a crosscutting COVID-19 Community Vulnerability Index (CCVI).		

List of Underlying Medical Conditions (adapted from CDC):

Phase 1b: Two or more conditions
Phase 3a: One or more conditions

- Cancer
- Chronic Kidney Disease
- COPD (Chronic Obstructive Pulmonary Disease) and other high-risk pulmonary disease
- Down Syndrome
- Heart Conditions, such as heart failure, coronary artery disease, or cardiomyopathies
- Immunocompromised states

- Obesity (body mass index of 30 kg/m or higher)
- Pregnancy
- Sickle cell disease
- Type 2 Diabetes Mellitus

Note: DPHS allows a health care provider to vaccinate any patient assessed to have significant risk for severe illness due to co-morbidities, even if not listed here. This list does not include every condition that might increase one's risk for developing severe illness from COVID-19, such as those for which evidence may be limited (e.g., rare conditions or combinations of conditions).